Status:
UNKNOWN
Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment
Lead Sponsor:
Central Hospital, Izmir
Conditions:
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18+ years
Brief Summary
The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronizatio...
Detailed Description
Background Cardiac implantable electronic devices (CIEDs) that are improving clinical outcomes in selected heart failure with reduced ejection fraction (HFrEF) patients also collect valuable diagnosti...
Eligibility Criteria
Inclusion
- Patients will eligible if they had already taking Sacubitril/Valsartan for ≥2 weeks and had been implanted with CIED for ≥3 months. Additionally, eligible patients must have a CIED before Sacubitril/Valsartan prescription date.
Exclusion
- Patients younger than 18 years.
- Patients who not taking or taking \<2 weeks Sacubitril Valsartan
- Patients who had a CIED which not using OptiVol algoritm for impedance measurement.
- Patients with structural pulmonary disease
- Patients with obstructive sleep apnea syndrome who using a continuous positive airway pressure device
- Patients with CIED pocket abcess
Key Trial Info
Start Date :
February 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03359967
Start Date
February 12 2018
End Date
August 31 2018
Last Update
December 2 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.